Kees L M C Franken

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4668428/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Defining Discriminatory Antibody Fingerprints in Active and Latent Tuberculosis. Frontiers in Immunology, 2022, 13, 856906.	2.2	12
2	A third vaccination with a single TÂcell epitope confers protection in a murine model of SARS-CoV-2 infection. Nature Communications, 2022, 13, .	5.8	29
3	Interleukin-6 and Mycobacterium tuberculosis dormancy antigens improve diagnosis of tuberculosis. Journal of Infection, 2021, 82, 245-252.	1.7	19
4	Interleukinâ€6â€mediated resistance to immunotherapy is linked to impaired myeloid cell function. International Journal of Cancer, 2021, 148, 211-225.	2.3	13
5	IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors. , 2021, 9, e002460.		10
6	In-vivo expressed Mycobacterium tuberculosis antigens recognised in three mouse strains after infection and BCG vaccination. Npj Vaccines, 2021, 6, 81.	2.9	8
7	BCG-induced immunity profiles in household contacts of leprosy patients differentiate between protection and disease. Vaccine, 2021, 39, 7230-7237.	1.7	6
8	An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AML. Cancers, 2021, 13, 5390.	1.7	3
9	Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal cancer. Oncolmmunology, 2020, 9, 1673125.	2.1	40
10	Peptide Binding to HLA-E Molecules in Humans, Nonhuman Primates, and Mice Reveals Unique Binding Peptides but Remarkably Conserved Anchor Residues. Journal of Immunology, 2020, 205, 2861-2872.	0.4	19
11	Selection of a Single Domain Antibody, Specific for an HLA-Bound Epitope of the Mycobacterial Ag85B Antigen. Frontiers in Immunology, 2020, 11, 577815.	2.2	3
12	Cell-Mediated Immune Responses to in vivo-Expressed and Stage-Specific Mycobacterium tuberculosis Antigens in Latent and Active Tuberculosis Across Different Age Groups. Frontiers in Immunology, 2020, 11, 103.	2.2	21
13	Use of resuscitation promoting factors to screen for tuberculosis infection in household-exposed children in The Gambia. BMC Infectious Diseases, 2020, 20, 469.	1.3	1
14	Application of new host biomarker profiles in quantitative point-of-care tests facilitates leprosy diagnosis in the field. EBioMedicine, 2019, 47, 301-308.	2.7	38
15	Production and Thermal Exchange of Conditional Peptideâ€MHC I Multimers. Current Protocols in Immunology, 2019, 126, e85.	3.6	13
16	Two-Hit in vitro T-Cell Stimulation Detects Mycobacterium tuberculosis Infection in QuantiFERON Negative Tuberculosis Patients and Healthy Contacts From Ghana. Frontiers in Immunology, 2019, 10, 1518.	2.2	10
17	BCG revaccination boosts adaptive polyfunctional Th1/Th17 and innate effectors in IGRA+ and IGRA– Indian adults. JCI Insight, 2019, 4, .	2.3	48
18	Apparent Lack of BRAFV600E Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8+ T Cells in Langerhans Cell Histiocytosis. Frontiers in Immunology, 2019, 10, 3045.	2.2	4

#	Article	IF	CITATIONS
19	Meeting report: the Leprosy Research Initiative Spring Meeting. Leprosy Review, 2019, 90, 183-200.	0.1	Ο
20	Functional CD169 on Macrophages Mediates Interaction with Dendritic Cells for CD8+ T Cell Cross-Priming. Cell Reports, 2018, 22, 1484-1495.	2.9	106
21	Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials. Nature Communications, 2018, 9, 358.	5.8	47
22	Detailed characterization of human <i>Mycobacterium tuberculosis</i> specific HLAâ€E restricted CD8 ⁺ TÂcells. European Journal of Immunology, 2018, 48, 293-305.	1.6	39
23	Vaccines for Leprosy and Tuberculosis: Opportunities for Shared Research, Development, and Application. Frontiers in Immunology, 2018, 9, 308.	2.2	23
24	Potential of DosR and Rpf antigens from Mycobacterium tuberculosis to discriminate between latent and active tuberculosis in a tuberculosis endemic population of Medellin Colombia. BMC Infectious Diseases, 2018, 18, 26.	1.3	34
25	lgA and IgG against Mycobacterium tuberculosis Rv2031 discriminate between pulmonary tuberculosis patients, Mycobacterium tuberculosis-infected and non-infected individuals. PLoS ONE, 2018, 13, e0190989.	1.1	27
26	Differences in IgG responses against infection phase related Mycobacterium tuberculosis (Mtb) specific antigens in individuals exposed or not to Mtb correlate with control of TB infection and progression. Tuberculosis, 2017, 106, 25-32.	0.8	24
27	Association of ESAT-6/CFP-10-induced IFN-γ, TNF-α and IL-10 with clinical tuberculosis: evidence from cohorts of pulmonary tuberculosis patients, household contacts and community controls in an endemic setting. Clinical and Experimental Immunology, 2017, 189, 241-249.	1.1	17
28	Humoral Responses to Rv1733c, Rv0081, Rv1735c, and Rv1737c DosR Regulon-Encoded Proteins of Mycobacterium tuberculosis in Individuals with Latent Tuberculosis Infection. Journal of Immunology Research, 2017, 2017, 1-8.	0.9	23
29	Uptake of HLA Alloantigens via CD89 and CD206 Does Not Enhance Antigen Presentation by Indirect Allorecognition. Journal of Immunology Research, 2016, 2016, 1-12.	0.9	1
30	The Breadth of Synthetic Long Peptide Vaccine-Induced CD8+ T Cell Responses Determines the Efficacy against Mouse Cytomegalovirus Infection. PLoS Pathogens, 2016, 12, e1005895.	2.1	16
31	Evaluation of cytokine responses against novel Mtb antigens as diagnostic markers for TB disease. Journal of Infection, 2016, 73, 219-230.	1.7	28
32	New Genome-Wide Algorithm Identifies Novel In-Vivo Expressed Mycobacterium Tuberculosis Antigens Inducing Human T-Cell Responses with Classical and Unconventional Cytokine Profiles. Scientific Reports, 2016, 6, 37793.	1.6	69
33	Multifunctional T Cell Response to DosR and Rpf Antigens Is Associated with Protection in Long-Term Mycobacterium tuberculosis-Infected Individuals in Colombia. Vaccine Journal, 2016, 23, 813-824.	3.2	31
34	Dynamics of the T cell response to Mycobacterium tuberculosis DosR and Rpf antigens in a Colombian population of household contacts of recently diagnosed pulmonary tuberculosis patients. Tuberculosis, 2016, 97, 97-107.	0.8	7
35	Detection of IgG1 antibodies against Mycobacterium tuberculosis DosR and Rpf antigens in tuberculosis patients before and after chemotherapy. Tuberculosis, 2016, 96, 65-70.	0.8	17
36	Multi-center evaluation of a user-friendly lateral flow assay to determine IP-10 and CCL4 levels in blood of TB and non-TB cases in Africa. Clinical Biochemistry, 2016, 49, 22-31.	0.8	49

#	Article	IF	CITATIONS
37	IFN-Î ³ and IgA against non-methylated heparin-binding hemagglutinin as markers of protective immunity and latent tuberculosis: Results of a longitudinal study from an endemic setting. Journal of Infection, 2016, 72, 189-200.	1.7	15
38	Longitudinal immune profiles in type 1 leprosy reactions in Bangladesh, Brazil, Ethiopia and Nepal. BMC Infectious Diseases, 2015, 15, 477.	1.3	60
39	Pro- and Anti-Inflammatory Cytokines against Rv2031 Are Elevated during Latent Tuberculosis: A Study in Cohorts of Tuberculosis Patients, Household Contacts and Community Controls in an Endemic Setting. PLoS ONE, 2015, 10, e0124134.	1.1	41
40	Synthetic Long Peptide Derived from Mycobacterium tuberculosis Latency Antigen Rv1733c Protects against Tuberculosis. Vaccine Journal, 2015, 22, 1060-1069.	3.2	32
41	Local and systemic XAGE-1b-specific immunity in patients with lung adenocarcinoma. Cancer Immunology, Immunotherapy, 2015, 64, 1109-1121.	2.0	11
42	The viral context instructs the redundancy of costimulatory pathways in driving CD8+ T cell expansion. ELife, 2015, 4, .	2.8	48
43	Clonal Analysis of the T-Cell Response to In Vivo Expressed Mycobacterium tuberculosis Protein Rv2034, Using a CD154 Expression Based T-Cell Cloning Method. PLoS ONE, 2014, 9, e99203.	1.1	14
44	Host Cytokine Responses Induced after Overnight Stimulation with Novel M. tuberculosis Infection Phase-Dependent Antigens Show Promise as Diagnostic Candidates for TB Disease. PLoS ONE, 2014, 9, e102584.	1.1	30
45	Field-Evaluation of a New Lateral Flow Assay for Detection of Cellular and Humoral Immunity against Mycobacterium leprae. PLoS Neglected Tropical Diseases, 2014, 8, e2845.	1.3	59
46	Immunogenicity of 60 novel latency-related antigens of Mycobacterium tuberculosis. Frontiers in Microbiology, 2014, 5, 517.	1.5	86
47	Use of Resuscitation-Promoting Factor Proteins Improves the Sensitivity of Culture-based Tuberculosis Testing in Special Samples. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 612-614.	2.5	22
48	Therapeutic immunization and local lowâ€dose tumor irradiation, a reinforcing combination. International Journal of Cancer, 2014, 134, 859-872.	2.3	38
49	Excision Repair Cross-Complementation group 1 (ERCC1) C118T SNP does not affect cellular response to oxaliplatin. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2014, 759, 37-44.	0.4	11
50	Longitudinal Immune Responses and Gene Expression Profiles in Type 1 Leprosy Reactions. Journal of Clinical Immunology, 2014, 34, 245-255.	2.0	63
51	The human peptidylarginine deiminases type 2 and type 4 have distinct substrate specificities. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 829-836.	1.1	48
52	The in vivo expressed Mycobacterium tuberculosis (IVE-TB) antigen Rv2034 induces CD4+ T-cells that protect against pulmonary infection in HLA-DR transgenic mice and guinea pigs. Vaccine, 2014, 32, 3580-3588.	1.7	25
53	Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and Tâ€cell activation. European Journal of Immunology, 2013, 43, 2554-2565.	1.6	157
54	The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study. Cancer Immunology, Immunotherapy, 2013, 62, 489-501.	2.0	16

#	Article	IF	CITATIONS
55	Interferon- \hat{I}^3 responses to Mycobacterium tuberculosis Rpf proteins in contact investigation. Tuberculosis, 2013, 93, 612-617.	0.8	13
56	An Unbiased Genome-Wide <i>Mycobacterium tuberculosis</i> Gene Expression Approach To Discover Antigens Targeted by Human T Cells Expressed during Pulmonary Infection. Journal of Immunology, 2013, 190, 1659-1671.	0.4	83
57	IgA Response to <scp>ESAT</scp> â€6/ <scp>CFP</scp> â€10 and <scp>R</scp> v2031 Antigens Varies in Patients With Cultureâ€Confirmed Pulmonary Tuberculosis, Healthy <i><scp>M</scp>ycobacterium tuberculosis–</i> Infected and Nonâ€Infected Individuals in a Tuberculosis Endemic Setting, <scp>E</scp> thiopia. Scandinavian Journal of ImmunoJogv. 2013. 78. 266-274.	1.3	31
58	CD27-CD70 Costimulation Controls T Cell Immunity during Acute and Persistent Cytomegalovirus Infection. Journal of Virology, 2013, 87, 6851-6865.	1.5	66
59	Analysis of Host Responses to Mycobacterium tuberculosis Antigens in a Multi-Site Study of Subjects with Different TB and HIV Infection States in Sub-Saharan Africa. PLoS ONE, 2013, 8, e74080.	1.1	48
60	Peptides Derived fromMycobacterium lepraeML1601c Discriminate between Leprosy Patients and Healthy Endemic Controls. Journal of Tropical Medicine, 2012, 2012, 1-11.	0.6	16
61	CD8 T cell autoreactivity to preproinsulin epitopes with very low human leucocyte antigen class I binding affinity. Clinical and Experimental Immunology, 2012, 170, 57-65.	1.1	41
62	A multistage-polyepitope vaccine protects against Mycobacterium tuberculosis infection in HLA-DR3 transgenic mice. Vaccine, 2012, 30, 7513-7521.	1.7	27
63	Analysis of Immune Responses against a Wide Range of Mycobacterium tuberculosis Antigens in Patients with Active Pulmonary Tuberculosis. Vaccine Journal, 2012, 19, 1907-1915.	3.2	61
64	New Biomarkers with Relevance to Leprosy Diagnosis Applicable in Areas Hyperendemic for Leprosy. Journal of Immunology, 2012, 188, 4782-4791.	0.4	73
65	Mycobacterium leprae virulence-associated peptides are indicators of exposure to M. leprae in Brazil, Ethiopia and Nepal. Memorias Do Instituto Oswaldo Cruz, 2012, 107, 112-123.	0.8	17
66	Potential of novel Mycobacterium tuberculosis infection phase-dependent antigens in the diagnosis of TB disease in a high burden setting. BMC Infectious Diseases, 2012, 12, 10.	1.3	63
67	Infliximab partially impairs the antiâ€ <i>Mycobacterium tuberculosis</i> immune responses of severe psoriasis patients with positive tuberculin skinâ€test. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 319-324.	1.3	3
68	T cell responses to DosR and Rpf proteins in actively and latently infected individuals from Colombia. Tuberculosis, 2012, 92, 148-159.	0.8	50
69	Potential of Host Markers Produced by Infection Phase-Dependent Antigen-Stimulated Cells for the Diagnosis of Tuberculosis in a Highly Endemic Area. PLoS ONE, 2012, 7, e38501.	1.1	50
70	Simultaneous Immunization against Tuberculosis. PLoS ONE, 2011, 6, e27477.	1.1	30
71	Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers. Journal of Autoimmunity, 2011, 37, 151-159.	3.0	66
72	Effect of vesicle size on tissue localization and immunogenicity of liposomal DNA vaccines. Vaccine, 2011. 29. 4761-4770.	1.7	65

#	Article	IF	CITATIONS
73	Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nature Immunology, 2011, 12, 45-53.	7.0	94
74	Double―and monofunctional CD4 ⁺ and CD8 ⁺ T ell responses to <i>Mycobacterium tuberculosis</i> DosR antigens and peptides in longâ€ŧerm latently infected individuals. European Journal of Immunology, 2011, 41, 2925-2936.	1.6	101
75	T-Cell Immune Function in Tumor, Skin, and Peripheral Blood of Advanced Stage Melanoma Patients: Implications for Immunotherapy. Clinical Cancer Research, 2011, 17, 5736-5747.	3.2	33
76	Identification of Human T-Cell Responses to Mycobacterium tuberculosis Resuscitation-Promoting Factors in Long-Term Latently Infected Individuals. Vaccine Journal, 2011, 18, 676-683.	3.2	67
77	PS13 - 67. Why islet-specific cytotoxic T-cells escape the thymus. Nederlands Tijdschrift Voor Diabetologie, 2011, 9, 136-136.	0.0	0
78	ML1419c Peptide Immunization Induces <i>Mycobacterium leprae</i> -Specific HLA-A*0201–Restricted CTL In Vivo with Potential To Kill Live Mycobacteria. Journal of Immunology, 2011, 187, 1393-1402.	0.4	12
79	CXCR6 Is a Marker for Protective Antigen-Specific Cells in the Lungs after Intranasal Immunization against Mycobacterium tuberculosis. Infection and Immunity, 2011, 79, 3328-3337.	1.0	55
80	Higher Frequency of T-Cell Response to M. tuberculosis Latency Antigen Rv2628 at the Site of Active Tuberculosis Disease than in Peripheral Blood. PLoS ONE, 2011, 6, e27539.	1.1	54
81	Development of a Mouse Food Pad Model for Detection of Sub Clinical Leprosy. Leprosy Review, 2011, 82, 432-444.	0.1	8
82	Immunogenicity of Mycobacterium leprae unique antigens in leprosy endemic populations in Asia and Africa. Leprosy Review, 2011, 82, 445-458.	0.1	7
83	Immunogenicity of Mycobacterium leprae unique antigens in leprosy endemic populations in Asia and Africa. Leprosy Review, 2011, 82, 445-58.	0.1	7
84	Increased IgG1, IFN-γ, TNF-α and IL-6 responses to Mycobacterium tuberculosis antigens in patients with Tuberculosis are lower after chemotherapy. International Immunology, 2010, 22, 775-782.	1.8	68
85	Decrease in Mycobacterium tuberculosis specific immune responses in patients with untreated psoriasis living in a tuberculosis endemic area. Archives of Dermatological Research, 2010, 302, 255-262.	1.1	16
86	Identification of citrullinated vimentin peptides as T cell epitopes in HLA–DR4–positive patients with rheumatoid arthritis. Arthritis and Rheumatism, 2010, 62, 117-125.	6.7	103
87	Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4 positive RA patients. Annals of the Rheumatic Diseases, 2010, 69, A74-A74.	0.5	0
88	Enhancing Sensitivity of Detection of Immune Responses to <i>Mycobacterium leprae</i> Peptides in Whole-Blood Assays. Vaccine Journal, 2010, 17, 993-1004.	3.2	25
89	Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 11895-11899.	3.3	215
90	Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. European Respiratory Journal, 2010, 36, 135-142.	3.1	119

#	Article	IF	CITATIONS
91	Evaluation of Immunological Crossâ€Reactivity between Clade A9 Highâ€Risk Human Papillomavirus Types on the Basis of E6â€Specific CD4 ⁺ Memory T Cell Responses. Journal of Infectious Diseases, 2010, 202, 1200-1211.	1.9	13
92	Simultaneous Detection of Circulating Autoreactive CD8+ T-Cells Specific for Different Islet Cell–Associated Epitopes Using Combinatorial MHC Multimers. Diabetes, 2010, 59, 1721-1730.	0.3	187
93	Serodiagnosis of tuberculous lymphadenitis using a combination of antigens. Journal of Infection in Developing Countries, 2010, 4, 096-102.	0.5	10
94	Cross-Reactive Immunity to <i>Mycobacterium tuberculosis</i> DosR Regulon-Encoded Antigens in Individuals Infected with Environmental, Nontuberculous Mycobacteria. Infection and Immunity, 2009, 77, 5071-5079.	1.0	54
95	From Genome-Based In Silico Predictions to Ex Vivo Verification of Leprosy Diagnosis. Vaccine Journal, 2009, 16, 352-359.	3.2	45
96	Immunogenicity of Novel DosR Regulon-Encoded Candidate Antigens of <i>Mycobacterium tuberculosis</i> in Three High-Burden Populations in Africa. Vaccine Journal, 2009, 16, 1203-1212.	3.2	148
97	DCâ€induced CD8 ⁺ Tâ€cell response is inhibited by MHC class IIâ€dependent DX5 ⁺ CD4 ⁺ Treg. European Journal of Immunology, 2009, 39, 1765-1773.	1.6	9
98	Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA–PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice. Vaccine, 2009, 27, 4010-4017.	1.7	103
99	Identification of T-Cell Antigens Specific for Latent Mycobacterium Tuberculosis Infection. PLoS ONE, 2009, 4, e5590.	1.1	126
100	Prediction of the immunogenic potential of frameshiftâ€mutated antigens in microsatellite instable cancer. International Journal of Cancer, 2008, 123, 838-845.	2.3	29
101	Superior induction of antiâ€ŧumor CTL immunity by extended peptide vaccines involves prolonged, DCâ€focused antigen presentation. European Journal of Immunology, 2008, 38, 1033-1042.	1.6	171
102	Rational Combination of Peptides Derived from Different <i>Mycobacterium leprae</i> Proteins Improves Sensitivity for Immunodiagnosis of <i>M. leprae</i> Infection. Vaccine Journal, 2008, 15, 522-533.	3.2	43
103	Balancing between Antitumor Efficacy and Autoimmune Pathology in T-Cell–Mediated Targeting of Carcinoembryonic Antigen. Cancer Research, 2008, 68, 8446-8455.	0.4	57
104	T-Cell Recognition of the HspX Protein of Mycobacterium tuberculosis Correlates with Latent M. tuberculosis Infection but Not with M. bovis BCG Vaccination. Infection and Immunity, 2007, 75, 2914-2921.	1.0	107
105	Immunogenicity of Eight Dormancy Regulon-Encoded Proteins of Mycobacterium tuberculosis in DNA-Vaccinated and Tuberculosis-Infected Mice. Infection and Immunity, 2007, 75, 941-949.	1.0	138
106	Lack of Immune Responses to Mycobacterium tuberculosis DosR Regulon Proteins following Mycobacterium bovis BCG Vaccination. Infection and Immunity, 2007, 75, 3523-3530.	1.0	96
107	Detection of Mycobacterium leprae infection employing a combinatorial approach of anti-45 kDa and modified anti-PGL-I antibody detection assays. Journal of Medical Microbiology, 2007, 56, 1129-1130.	0.7	2
108	Serological heterogeneity against various Mycobacterium leprae antigens and its use in serodiagnosis of leprosy patients. Journal of Medical Microbiology, 2007, 56, 1259-1261.	0.7	2

#	Article	IF	CITATIONS
109	Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists. Vaccine, 2007, 25, 1379-1389.	1.7	46
110	CD8+ CTL Priming by Exact Peptide Epitopes in Incomplete Freund's Adjuvant Induces a Vanishing CTL Response, whereas Long Peptides Induce Sustained CTL Reactivity. Journal of Immunology, 2007, 179, 5033-5040.	0.4	221
111	Evaluation of Recombinant Serine-rich 45-kDa Antigen (MLO411) for Detection of Antibodies in Leprosy Patients. Scandinavian Journal of Immunology, 2007, 65, 310-310.	1.3	0
112	Adenovirus-Specific CD4+T Cell Clones Recognizing Endogenous Antigen Inhibit Viral Replication In Vitro through Cognate Interaction. Journal of Immunology, 2006, 177, 8851-8859.	0.4	42
113	The Impact of Single Amino Acid Substitutions in CD3γ on the CD3ïµÎ³ Interaction and T-Cell Receptor–CD3 Complex Formation. Human Immunology, 2006, 67, 579-588.	1.2	9
114	Evaluation of Recombinant Serine-rich 45-kDa Antigen (ML0411) for Detection of Antibodies in Leprosy Patients. Scandinavian Journal of Immunology, 2006, 64, 450-455.	1.3	15
115	Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nature Medicine, 2006, 12, 417-424.	15.2	142
116	Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes and Infection, 2006, 8, 2052-2060.	1.0	262
117	Monokine induced by interferon gamma and IFN-γ response to a fusion protein of Mycobacterium tuberculosis ESAT-6 and CFP-10 in Brazilian tuberculosis patients. Microbes and Infection, 2006, 8, 45-51.	1.0	46
118	Rapid assessment of the antigenic integrity of tetrameric HLA complexes by human monoclonal HLA antibodies. Journal of Immunological Methods, 2006, 315, 153-161.	0.6	9
119	Human CD4+ T cells stimulated by conserved adenovirus 5 hexon peptides recognize cells infected with different species of human adenovirus. European Journal of Immunology, 2006, 36, 2410-2423.	1.6	38
120	SPI-CI and SPI-6 cooperate in the protection from effector cell–mediated cytotoxicity. Blood, 2005, 105, 1153-1161.	0.6	50
121	T cell immune responses to mycobacterial antigens in Brazilian tuberculosis patients and controls. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2005, 99, 699-707.	0.7	22
122	Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis, 2005, 85, 29-38.	0.8	154
123	Rapid enrichment of human papillomavirus (HPV)â€specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer. International Journal of Cancer, 2005, 114, 274-282.	2.3	22
124	ESAT-6/CFP-10 Fusion Protein and Peptides for Optimal Diagnosis of Mycobacterium tuberculosis Infection by Ex Vivo Enzyme-Linked Immunospot Assay in The Gambia. Journal of Clinical Microbiology, 2005, 43, 2070-2074.	1.8	50
125	Epstein-Barr Virus gp42 Is Posttranslationally Modified To Produce Soluble gp42 That Mediates HLA Class II Immune Evasion. Journal of Virology, 2005, 79, 841-852.	1.5	82
126	Postgenomic Approach To Identify Novel Mycobacterium leprae Antigens with Potential To Improve Immunodiagnosis of Infection. Infection and Immunity, 2005, 73, 5636-5644.	1.0	59

#	Article	IF	CITATIONS
127	Intraocular Tumor Antigen Drains Specifically to Submandibular Lymph Nodes, Resulting in an Abortive Cytotoxic T Cell Reaction. Journal of Immunology, 2004, 172, 1567-1574.	0.4	43
128	Immunological Crossreactivity of the Mycobacterium leprae CFP-10 with its Homologue in Mycobacterium tuberculosis. Scandinavian Journal of Immunology, 2004, 59, 66-70.	1.3	68
129	Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine, 2004, 22, 1609-1615.	1.7	171
130	Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model. Vaccine, 2004, 23, 305-311.	1.7	13
131	Magnitude and polarization of P53-specific T-helper immunity in connection to leukocyte infiltration of colorectal tumors. International Journal of Cancer, 2003, 107, 425-433.	2.3	28
132	Interferon-Î ³ Production in Response to M. Tuberculosis Antigens in Tb Patients in Indonesia. Advances in Experimental Medicine and Biology, 2003, 531, 249-260.	0.8	3
133	Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Research, 2003, 63, 636-41.	0.4	166
134	Identification and Characterization of the ESAT-6 Homologue of Mycobacterium leprae and T-Cell Cross-Reactivity with Mycobacterium tuberculosis. Infection and Immunity, 2002, 70, 2544-2548.	1.0	126
135	T-Cell Responses to the Mycobacterium tuberculosis- Specific Antigen ESAT-6 in Brazilian Tuberculosis Patients. Infection and Immunity, 2002, 70, 6707-6714.	1.0	66
136	Kinetics of T cell-activation molecules in response to Mycobacterium tuberculosis antigens. Memorias Do Instituto Oswaldo Cruz, 2002, 97, 1097-1099.	0.8	16
137	Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Research, 2002, 62, 472-9.	0.4	119
138	Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells. Cancer Research, 2002, 62, 6187-93.	0.4	46
139	Natural T-helper immunity against human papillomavirus type 16 (hpv16) e7-derived peptide epitopes in patients with hpv16-positive cervical lesions: Identification of 3 human leukocyte antigen class ii-restricted epitopes. International Journal of Cancer, 2001, 91, 612-618.	2.3	129
140	Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer. European Journal of Immunology, 2001, 31, 146-155.	1.6	53
141	Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 11515-11520.	3.3	299
142	Novel Salmonella enterica Serovar Typhimurium Protein That Is Indispensable for Virulence and Intracellular Replication. Infection and Immunity, 2001, 69, 7413-7418.	1.0	14
143	Cytomegalovirus in autoimmunity: T cell crossreactivity to viral antigen and autoantigen glutamic acid decarboxylase. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 3988-3991.	3.3	174
144	Identification of Major Epitopes of <i>Mycobacterium tuberculosis</i> AG85B That Are Recognized by HLA-A*0201-Restricted CD8+ T Cells in HLA-Transgenic Mice and Humans. Journal of Immunology, 2000, 165, 6463-6471.	0.4	152

9

#	Article	IF	CITATIONS
145	Purification of His-Tagged Proteins by Immobilized Chelate Affinity Chromatography: The Benefits from the Use of Organic Solvent. Protein Expression and Purification, 2000, 18, 95-99.	0.6	217
146	Increased intracellular survival of Mycobacterium smegmatis containing the Mycobacterium leprae thioredoxin-thioredoxin reductase gene. Infection and Immunity, 1997, 65, 2537-2541.	1.0	39
147	Gin mutants that can be suppressed by a Fis-independent mutation. Journal of Bacteriology, 1995, 177, 222-228.	1.0	8
148	Development of Human Cell-Based In Vitro Infection Models to Determine the Intracellular Survival of Mycobacterium avium. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	3